Tirzepatide is an FDA-approved prescription medication representing a groundbreaking dual agonist that simultaneously activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes mellitus (branded as Mounjaro), and for chronic weight management in adults with obesity (BMI \u226530) or overweight (BMI \u226527) with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea, as well as adolescents aged 12 years and older with obesity (branded as Zepbound). By targeting both GIP and GLP-1 pathways, Tirzepatide enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, reduces appetite, and increases satiety\u2014resulting in exceptional blood glucose regulation and profound body weight reduction. Landmark clinical trials (SURPASS for diabetes and SURMOUNT for weight management) show Tirzepatide achieves average A1C reductions of up to 2.4\u20132.6% and body weight losses of 15\u201325% or more (often 30\u201360 pounds or greater over 72 weeks at higher doses), frequently outperforming other GLP-1 therapies and delivering significant cardiometabolic benefits including improved lipid profiles, blood pressure, waist circumference, and liver fat content. Tirzepatide is administered once weekly via convenient pre-filled single-dose pens (subcutaneous injection in the abdomen, thigh, or upper arm), with a gradual dose escalation starting at 2.5mg and increasing in 2.5mg increments every 4 weeks (up to 15mg) to optimize tolerability and minimize gastrointestinal side effects such as nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, and injection-site reactions, which are usually transient and most prominent during dose initiation or escalation. While highly effective for both type 2 diabetes control and chronic weight management, Tirzepatide carries important safety considerations including a boxed warning for risk of thyroid C-cell tumors (including medullary thyroid carcinoma) observed in rodent studies\u2014contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2\u2014and potential risks of pancreatitis, gallbladder-related events, acute kidney injury, severe gastrointestinal disease exacerbation, hypersensitivity reactions, and hypoglycemia (when used with insulin or sulfonylureas). It is not recommended during pregnancy (due to potential fetal harm), breastfeeding, or in patients with severe gastroparesis. Tirzepatide should only be used under medical supervision with regular monitoring of glycemic control, weight, thyroid\/kidney function, and side effects. Avoid unapproved or compounded versions due to serious safety and quality risks. Always consult a healthcare provider before starting Tirzepatide to determine the appropriate brand, dosing schedule, and whether it aligns with your health goals as part of a comprehensive diabetes or weight management plan including lifestyle modifications.<\/p>\n